# Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

> **NCT06304545** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 48 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Chemotherapy
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT06304545
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2026-08-16
- **Final completion:** 2027-03-15
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304545, "Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06304545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*